CARDAMYST for Paroxysmal Supraventricular Tachycardia FDA Prescription Drug ... with atrial fibrillation with rapid ventricular rate (AFib-RVR) Phase 3 pivotal trial in AFib-RVR expected to ...
Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...
This patent pertains to the repeat dose regimen of CARDAMYST™, which demonstrated efficacy in the RAPID Phase 3 study for paroxysmal supraventricular tachycardia (PSVT). The issuance of this ...
CARDAMYST for Paroxysmal Supraventricular Tachycardia FDA Prescription Drug ... with atrial fibrillation with rapid ventricular rate (AFib-RVR) Phase 3 pivotal trial in AFib-RVR expected to ...
It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid ...
Hosted on MSN27d
H.C. Wainwright maintains $25 target on Milestone sharesAdditionally, Milestone Pharmaceuticals is planning to initiate a Phase 3 program in the first half of 2025 for atrial fibrillation with rapid ventricular rate (AFib-RVR). Success in this program ...
PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT ... to initiate Phase 3 Study in AFib-RVR in H1 2025 MONTREAL and CHARLOTTE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback